What is basal cell carcinoma? Basal cell carcinoma (BCC) is a skin cancer arising in basal cells in the lower part of the epidermis. It usually stays near its original site, but it can grow into surrounding tissue; a sore or growth that persists or changes needs assessment. NCI BCC description.
Confidence: high for biopsy-based diagnosis and the importance of treating local disease appropriately. Medicine and procedure choices below are attributed clinical context; this review does not assign an independently cleared product-effect score. BCC is distinct from melanoma and cutaneous squamous cell carcinoma.
- BCC usually stays local but can damage nearby skin, nerves and other structures.
- Persistent sores, changing growths and scar-like patches need assessment across skin tones.
- A biopsy identifies the cancer; every BCC does not need a full-body staging scan.
- Excision, Mohs and superficial treatments fit different lesions rather than a single universal rule.
- Selected systemic care has important risks; supplements cannot replace assessment or treatment.
Table of contents
- Evidence summary
- What BCC is: uncommon spread does not mean harmless
- Symptoms and appearance: a pearly bump is only one pattern
- How it develops: UV exposure and individual risk
- Biopsy, pathology and further tests
- Surgery and Mohs: removal, margins and tissue preservation
- Selected creams, light treatment and advanced-cancer medicines
- Safety and interactions: check the actual medicine and procedure
- Sun protection, nutrition and screening limits
- Who needs individual planning and what follow-up should record
- Research and trials: mechanism is not independent patient benefit
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
Clinical descriptions, care guidance and independently established treatment outcomes have different evidentiary roles. The table identifies what the reviewed sources can support and which financial or clinical questions remain unresolved.
| Question / approach | Evidence reviewed | Funding / conflicts | Interpretation / limits |
|---|---|---|---|
| Is infrequent spread reassuring enough? | NCI definition and supported AAD local-behaviour description. | Public route with study gaps; AAD explicitly Regeneron-supported, Tier 4/D. | Local damage still matters; descriptive role, no numerical outcome adopted. |
| How is a lesion diagnosed and removed? | Current NHS testing and NCI procedure context. | Page/contributor and underlying-study finances unclosed. | Tissue assessment and selected margin-control approaches. |
| What do creams or systemic medicines mean? | Supported AAD context and current manufacturer US label. | Industry-supported and applicant material Tier 4/D; excluded independent efficacy. | Selected superficial versus advanced indication, not interchangeable care. |
| Can prevention products replace treatment? | NHS protection and NCI prevention, screening and diet context. | Original product-study chains not financially cleared. | No cure substitute, app diagnosis or brand ranking established. |
What BCC is: uncommon spread does not mean harmless
Basal cell carcinoma and squamous cell carcinoma are the main non-melanoma skin cancers. Their names describe different cells; a result saying only “skin cancer” is not enough to select a treatment. BCC belongs to the epidermal skin-cancer group, rather than the pigment-cell cancer melanoma. Current NHS definition.
BCC can damage deeper skin, nerves, muscle or bone, including functional structures near an eyelid, nose or ear. AAD descriptive context.
This distinction matters when someone hears that the cancer is unlikely to metastasize. The clinical questions still include how far it extends locally, whether removal will preserve the nearby structure and whether it has returned after earlier treatment. Do not use the usual behaviour of BCC to label an unexplained lump yourself.
Symptoms and appearance: a pearly bump is only one pattern
Non-melanoma lesions may grow, change texture or colour, hurt, itch, bleed, crust or repeatedly scab. They can appear as discoloured or rough patches as well as raised growths, and may look darker on brown or black skin. September 2026 NHS symptoms.
NCI describes BCC as sometimes smooth and pearly, but also as a scar-like, firm or flat lesion. A textbook photograph therefore represents only one possible appearance. BCC appearance variants.
A changing or persistent skin lesion should be examined. The GP may arrange photographic specialist review or an urgent referral; referral indicates a need for investigation, not a confirmed cancer diagnosis. Clinical-assessment pathway.
Explain whether the same spot repeatedly opens and closes, when it changed, and previous treatment. Include locations hidden by hair or clothing. An image search cannot exclude cancer or provide tissue depth.
How it develops: UV exposure and individual risk
UV radiation from sunlight or tanning devices is a major cause. Non-melanoma skin cancer is more likely with older age and skin that burns easily, but people of any skin colour can develop it. Risk factors describe a probability, not a diagnosis. NHS UV and skin-colour context.
The NCI professional summary describes altered Hedgehog signalling in BCC. This biological pathway explains why selected advanced tumours may be considered for a pathway-targeting medicine; it does not prove that a supplement or laboratory compound is an effective treatment. Selected mechanism context.
Provide the clinician with a history of previous skin cancers, radiation treatment and immune-system medicines. A family history or repeated cancers at a young age may change the assessment, but this article does not diagnose an inherited syndrome from lesion counts. The importance of a new lesion is not cancelled by having avoided sunburn.
Biopsy, pathology and further tests
A specialist may examine the area with magnification and take a skin sample for laboratory testing. Further scans, lymph-gland tests or blood tests are selected according to the actual cancer. BCC seldom spreads, so a full-body staging scan is not automatic for every biopsy-proven lesion. NHS testing pathway.
The pathology result identifies the cancer and helps explain the next step. Ask whether the sample was intended just to diagnose it or also to remove it, and whether any further assessment is needed before treatment. A lesion sampled in part should not be assumed fully treated because the visible wound has healed.
Keep the pathology report, site and earlier treatment details available. When a lesion has returned, tell the service how it was previously treated and whether the same area was biopsied before. Photographs can document location and change; they cannot replace the laboratory result or establish that surgical edges are clear.
Surgery and Mohs: removal, margins and tissue preservation
Surgery is a main treatment for non-melanoma skin cancer. Removing a larger area may require a skin graft or another repair. Selected patients may instead receive radiotherapy, for example when surgery is difficult or the person is too unwell for it. Current NHS local-treatment context.
Excision removes the tumour with surrounding tissue. In Mohs micrographic surgery, thin layers are removed and examined microscopically at the edges until no cancer remains in the examined margins. This can preserve tissue in selected sensitive sites or poorly defined lesions. NCI procedure distinction.
Ask why the proposed method fits the lesion’s site and pathology, how the margins will be assessed and how the wound will be repaired. The visible diameter alone is not a surgical-margin prescription. This guide does not choose Mohs for every BCC or give a numerical cure-rate comparison drawn from incompletely cleared studies.
Clarify who communicates the final pathology and who manages the wound. A normal-looking scar is not a pathology margin report.
Selected creams, light treatment and advanced-cancer medicines
Topical care is selected for superficial BCC. Redness, swelling, crusting, blistering or discomfort needs a planned contact; deeper disease requires separate assessment. Supported AAD topical context.
The NHS also describes selected photodynamic treatment for disease that has not extended deeply, and selected targeted medicines or immunotherapy. These categories do not mean that every non-melanoma cancer is suitable for every method. Current treatment families.
The current US cemiplimab label includes selected adults with locally advanced or metastatic BCC previously treated with a Hedgehog inhibitor, or for whom that approach is inappropriate. This is an indication boundary, not a recommendation for every BCC. August 2026 US label scope.
Advanced disease needs a specialist discussion about what is treatable locally and the purpose of systemic care. A targeted pathway and an immune checkpoint are different mechanisms. Neither a medicine’s approval nor an educational page supported by its seller establishes a financially independent comparison with other care. Local licensing and access can differ from the US label.
Safety and interactions: check the actual medicine and procedure
Cemiplimab can cause severe or fatal immune reactions, including lung, bowel, liver, kidney or endocrine inflammation and solid-organ transplant rejection. Effects may appear after treatment stops. New breathing difficulty, severe diarrhoea or a rapidly serious reaction needs prompt medical assessment using the team’s emergency plan. Selected current serious warnings.
NCI describes interactions between anticancer drugs and foods or concentrated supplements, including St John’s wort and grapefruit. These are drug-specific; an ingredient review is more useful than either a universal ban or a claim that natural products are harmless. Interaction evidence limits.
Before a procedure, provide the team with all medicines, including anticoagulants and antiplatelet drugs, and follow its instructions rather than stopping them yourself. Before systemic treatment, list supplements, herbal products and medicines from other clinics. The purpose is to reconcile the complete plan, not to make a self-directed dose change.
Obtain a contact for treatment reactions and wound-care instructions. An unexpected problem is not proof that treatment is working. Personal topical schedules and toxicity treatment require the clinical team.
Sun protection, nutrition and screening limits
The NHS advises reducing UV exposure, protecting skin with clothing and suitable sunscreen, and avoiding tanning devices. Protection supports future risk reduction; it does not remove a BCC already present. Local UV conditions matter rather than a universal UK clock-time rule. Practical protection guidance.
NCI distinguishes prevention advice from uncertainties in particular cancer-endpoint trials. This guide makes no numerical prevention guarantee, ranks no sunscreen brands and identifies no oral product that replaces UV protection or cancer treatment. Prevention evidence boundary.
Screening people without symptoms differs from diagnosing an existing suspicious spot. It can produce false-positive or false-negative findings and biopsy harms. NCI says skin-assessment apps still need further large-scale validation. Screening and app limits.
NCI separates nutrition support from claims that foods, vitamins, herbs or restrictive diets cure cancer or stop its return. A supplement should not replace lesion assessment or prescribed treatment; ingredients should be checked with the care team. Diet and supplement distinction.
Who needs individual planning and what follow-up should record
Transplantation and immune-suppressing medicines affect planning. Some BCC medicines harm pregnancy; discuss these circumstances without independently stopping necessary treatment. Individual-risk context.
NCI describes an individualized follow-up plan and treatment summary containing the pathology, procedures and medicines. New concerns should be reported between visits; the actual disease and treatment determine the review schedule. Follow-up record and contact.
For BCC, keep the exact skin site, treatment method and final margin information with the care record. Ask who checks the treated area and who assesses other skin lesions. A change at the old site and a new spot elsewhere are different assessment questions, even though both may need examination. There is no universal scan interval or home rule to declare follow-up finished.
Research and trials: mechanism is not independent patient benefit
Clinical trials study new ways to prevent, diagnose or treat cancer and manage its problems. A trial has eligibility, consent and experimental questions; being listed does not prove superiority or suitability for an individual. Trial-participation context.
A useful BCC comparison assesses sustained local control, recurrence, function, harms and care burden. Laboratory growth inhibition and animal tumour responses cannot substitute for these human outcomes; short-term response is not lasting control.
This review excludes industry-supported outcome claims from its independent efficacy verdict, while retaining clearly attributed indication and safety information. The funding table distinguishes the public NCI route, known reviewer interests, society revenue and explicit manufacturer support. No pooled estimate or product ranking is supplied when the underlying financial chains have not been independently closed.
Funding and source roles
Research funding at a glance
25 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
The source-specific map separates documented institutional funding from disease-page payments and trial sponsorship. Unknown allocations remain unknown. A public agency, charity or academic address does not by itself establish independent treatment efficacy.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NHS non-melanoma skin cancer definition | National website policy; fiscal route and limits in the separate policy row. Exact contributor and study finances unclosed. | United Kingdom; national NHS website, not an individual provider trust. | Tier 2 public clinical context, provisional. | B, provisional — actual 16 September 2026 body read; clinical accountability supports checking. Page allocation, expert interests, simplification and local-pathway limits remain. |
| NHS non-melanoma skin cancer symptoms | National website policy; fiscal route and limits in the separate policy row. Exact contributor and study finances unclosed. | United Kingdom; national NHS website, not an individual provider trust. | Tier 2 public clinical context, provisional. | B, provisional — actual 16 September 2026 body read; clinical accountability supports checking. Page allocation, expert interests, simplification and local-pathway limits remain. |
| NHS non-melanoma skin cancer causes | National website policy; fiscal route and limits in the separate policy row. Exact contributor and study finances unclosed. | United Kingdom; national NHS website, not an individual provider trust. | Tier 2 public clinical context, provisional. | B, provisional — actual 16 September 2026 body read; clinical accountability supports checking. Page allocation, expert interests, simplification and local-pathway limits remain. |
| NHS non-melanoma skin cancer tests | National website policy; fiscal route and limits in the separate policy row. Exact contributor and study finances unclosed. | United Kingdom; national NHS website, not an individual provider trust. | Tier 2 public clinical context, provisional. | B, provisional — actual 16 September 2026 body read; clinical accountability supports checking. Page allocation, expert interests, simplification and local-pathway limits remain. |
| NHS non-melanoma skin cancer treatment | National website policy; fiscal route and limits in the separate policy row. Exact contributor and study finances unclosed. | United Kingdom; national NHS website, not an individual provider trust. | Tier 2 public clinical context, provisional. | B, provisional — actual 16 September 2026 body read; clinical accountability supports checking. Page allocation, expert interests, simplification and local-pathway limits remain. |
| NCI skin cancer patient PDQ | Derived professional version and named lead; separate January/February 2026 disclosure records consulting/advisory interests. NCI fiscal routes are in dedicated profiles. Later relationships are not payment attribution to this page; source-trial contracts unclosed. | United States; NCI/NIH/HHS, Bethesda, Maryland; federal jurisdiction. | Tier 3 derived source with disclosed professional reviewer relationships. | C, provisional — actual patient derivation and professional lead credit read. Khan’s later relevant interests and incompletely public member/study finances limit independence; no page payment or product efficacy inferred. |
| NCI skin cancer health-professional PDQ | Federal appropriations and gift routes; named lead reviewer Shaheer A. Khan. January/February 2026 disclosure reports relevant consulting/advisory ties. Later interests do not prove payment for this page; underlying study contracts unclosed. | United States; NCI/NIH/HHS, Bethesda, Maryland; federal jurisdiction. | Tier 3 source with disclosed reviewer commercial relationships. | C, provisional — actual credited reviewer and separate later declaration read. Expert review supports checking; known relevant interests and incompletely public PDQ member/trial finances limit independence. |
| NCI skin cancer prevention patient PDQ | Congressional appropriations; separate gift routes. Page, contributor and underlying-study allocations unclosed. | United States; NCI/NIH/HHS, Bethesda, Maryland; federal jurisdiction. | Tier 2 clinical context, provisional; underlying studies not financially cleared. | B, provisional — expert review and public accountability support accuracy; updated 16 May 2025; PDQ board-specific interests are not fully published. Not a treatment guideline. |
| NCI skin cancer screening patient PDQ | Congressional appropriations; separate gift routes. Page, contributor and underlying-study allocations unclosed. | United States; NCI/NIH/HHS, Bethesda, Maryland; federal jurisdiction. | Tier 2 clinical context, provisional; underlying studies not financially cleared. | B, provisional — expert review and public accountability support accuracy; actual selected body read; PDQ board-specific interests are not fully published. Not a treatment guideline. |
| NCI diets and supplements | Congressional appropriations; separate gift routes. Page, contributor and underlying-study allocations unclosed. | United States; NCI/NIH/HHS, Bethesda, Maryland; federal jurisdiction. | Tier 2 clinical context, provisional; underlying studies not financially cleared. | B, provisional — expert review and public accountability support accuracy; posted 30 October 2024; Institutional mission and unclosed page/contributor interests remain. |
| NCI food and supplement interactions PDQ | Congressional appropriations; separate gift routes. Page, contributor and underlying-study allocations unclosed. | United States; NCI/NIH/HHS, Bethesda, Maryland; federal jurisdiction. | Tier 2 clinical context, provisional; underlying studies not financially cleared. | B, provisional — expert review and public accountability support accuracy; updated 25 April 2024; PDQ board-specific interests are not fully published. Not a treatment guideline. |
| NCI follow-up medical care | Congressional appropriations; separate gift routes. Page, contributor and underlying-study allocations unclosed. | United States; NCI/NIH/HHS, Bethesda, Maryland; federal jurisdiction. | Tier 2 clinical context, provisional; underlying studies not financially cleared. | B, provisional — expert review and public accountability support accuracy; actual selected body read; Institutional mission and unclosed page/contributor interests remain. |
| NCI clinical-trial overview | Congressional appropriations; separate gift routes. Page, contributor and underlying-study allocations unclosed. | United States; NCI/NIH/HHS, Bethesda, Maryland; federal jurisdiction. | Tier 2 clinical context, provisional; underlying studies not financially cleared. | B, provisional — expert review and public accountability support accuracy; actual selected body read; Institutional mission and unclosed page/contributor interests remain. |
| AAD basal cell carcinoma patient guide | Disease page explicitly acknowledges Regeneron support, while stating AAD developed the content. Society income and corporate routes are separate. Exact grant, contract and contributor payments unclosed. | United States; AAD, Rosemont, Illinois. Regeneron headquarters documented separately in Tarrytown, New York. | Tier 4 industry-supported education; excluded independent efficacy. | D for independence — actual 1 October 2025 page and support footer read. Relevant product seller has commercial incentives; educational accountability does not remove sponsorship. Descriptive/safety context only. |
| AAD/AADA combined 2024 audited financial statements | Actual full 36-page audited report, selected note 2: dues, meetings/exhibits, journal royalties, educational products, grants and contributions. Corporate grants and licensing routes documented; exact disease-page sums unclosed. | United States; combined American Academy of Dermatology and Association. | Tier 3 institutional financial self-report with external audit. | B, provisional — audit and accounting detail support accuracy; institution reports its own finances, 2024 period and missing current page allocation remain. |
| AAD corporate-support programme | Actual programme page describes sponsorship/grants and corporate participation. Current 2026 heading and 2025 programme-support footer have different periods; no complete donor or contract ledger inferred. | United States; AAD, Rosemont, Illinois. | Tier 3 institutional funding self-report. | B, provisional — explicit commercial route; fundraising incentives, incomplete amounts and disease-page allocation remain. |
| AAD office/contact information | Society contact self-report; revenue routes are in separate audit and support profiles. | United States; 9500 W. Bryn Mawr Avenue, Suite 500, Rosemont, Illinois. Additional Washington office. | Tier 3 institutional identity self-report. | B, provisional — actual office body read; location does not establish evidence independence. |
| Shaheer A. Khan January/February 2026 financial disclosure | Actual three-page publisher original identifies advisory/consulting relationships with Regeneron, Ideaya Biosciences, Replimune and Immunocore. Interview/article financing and complete amounts unclosed; not payment attribution to May 2025 NCI skin page. | United States; disclosed author at Zucker School of Medicine, Hofstra University, Hempstead, New York. Complete backer jurisdictions not traced here. | Tier 3 author with relevant commercial relationships; financial-only. | C, provisional — explicit dated declaration helps accuracy. Full remuneration, publisher backers and page-period allocation unclosed; no clinical effect adopted. |
| Regeneron second-quarter 2026 financial report | Actual 30 July 2026 company report: product and collaboration revenues, including Libtayo, and shareholder/distribution routes. Complete ownership/control, education grants and disease-page allocations unclosed. | United States; headquarters separately documented in Tarrytown, New York. International commercial collaborations. | Tier 4 therapeutic-product seller self-report. | D for independence — direct commercial and investor incentives; dated financial disclosure is useful for tracing, not medicine efficacy. |
| Regeneron company locations | Company location self-report; actual income routes are in the separate financial profile. | United States; 777 Old Saw Mill River Road, Tarrytown, New York. No inference that all manufacturing occurs here. | Tier 4 product-seller identity source. | D for independence — company accurately identifying itself remains commercially interested. Manufacturing/subcontractor and ownership chains unclosed. |
| Cemiplimab US prescribing information, revised August 2026 | Regeneron manufacturer prescribing information held by NLM/DailyMed. Repository hosting does not remove applicant sponsorship. Complete trial funding/author contracts unclosed. | United States label/jurisdiction; Regeneron headquarters in Tarrytown, New York. Complete manufacturing chain not inferred. | Tier 4 manufacturer/applicant-derived medicine information. | D for independence — regulatory safety accountability is valuable, but seller/application data remain interested. Selected current warnings and indication only; numerical outcomes excluded. |
| NCI budget and appropriations, May 2026 | Congressional funding through HHS/NIH. Enacted appropriations and future requests differ; no disease-page amount assigned. | United States; NCI/NIH/HHS, Bethesda, Maryland. | Tier 3 institutional financial self-report. | B, provisional — actual budget process and dated body read; fiscal accountability, budget priorities and missing page allocation. |
| NCI Gift Fund and contribution routes, August 2025 | Public gifts/Gift Fund and Breast Cancer Research Stamp route separate from Congress. Named page donors and complete accepted receipts unclosed. | United States; 9000 Rockville Pike, Bethesda, Maryland; federal NCI. | Tier 3 institutional financial self-report. | B, provisional — actual contribution and headquarters text read; no named donor control or page sponsorship inferred. |
| NCI PDQ editorial boards, November 2022 | NCI support; non-government member honoraria/travel expenses. Declarations and recusal required; specific conflicts not publicly required. | United States; NCI, Bethesda, with international board contributors. | Tier 3 institutional process and payment self-report. | B, provisional — actual dated policy read; editorial independence does not clear member interests or sponsored underlying trials. |
| NHS national content policy, October 2022 | DHSC funding; policy states no advertising or corporate sponsorship. Full page/expert receipts unclosed. | United Kingdom; national NHS website. | Tier 3 financial/editorial self-report. | B, provisional — actual funding/accuracy policy read; next review due October 2025 passed. Not a provider-trust accounts profile. |
Frequently asked questions
Can basal cell carcinoma damage tissue if it usually does not spread? Yes. Its local growth can damage surrounding structures; uncommon distant spread is not a reason to ignore it. Local behaviour.
Does every BCC need Mohs surgery? No universal rule applies. The team considers the site, actual lesion and margin assessment; ask why the selected method fits. Procedure context.
Can a cream treat every basal cell carcinoma? No. Prescribed topical care is a selected option for superficial disease, not an automatic treatment for deep or recurrent BCC. Selected topical context.
Can darker skin or no sunburn rule BCC out? No. People of any skin colour can develop non-melanoma cancer, and risk history does not establish or exclude an individual diagnosis. Risk context.
Should I stop transplant or blood-thinning medicines before treatment? Do not make that decision from this article. Give the treating service the actual medication list and obtain coordinated instructions.
Sources and funding notes
Selected current NHS bodies were reviewed 16 September 2026. Selected NCI pathology, mechanism, screening, prevention and supportive-care originals were read. The patient PDQ expressly derives from the professional version naming Khan; his separate January/February 2026 commercial disclosure is not payment attribution to the May 2025 pages. The AAD disease guide expressly acknowledges Regeneron support and is excluded from independent efficacy. Its actual 2024 combined audit documents wider society revenue. The manufacturer’s August 2026 prescribing information supplies selected indication/safety context only; numerical effects, doses and comparative product claims are excluded. Full original-study contracts, page grants and individual remuneration remain unclosed. US and UK context does not establish worldwide licensing or access.
- NHS non-melanoma skin cancer definition — BCC versus SCC scope.
- NHS non-melanoma skin cancer symptoms — Changing or persistent lesions and referral.
- NHS non-melanoma skin cancer causes — UV risk and practical sun protection.
- NHS non-melanoma skin cancer tests — Biopsy and individually selected further tests.
- NHS non-melanoma skin cancer treatment — Selected surgery, radiotherapy and local/systemic care families.
- NCI skin cancer patient PDQ — Selected pathology, local behaviour and procedure context.
- NCI skin cancer health-professional PDQ — Selected mechanism and care categories; no independent product-effect estimate.
- NCI skin cancer prevention patient PDQ — Prevention endpoint uncertainty, not a brand ranking.
- NCI skin cancer screening patient PDQ — Asymptomatic screening versus diagnosis; app and biopsy limits.
- NCI diets and supplements — Nutrition versus unestablished cancer-cure claims.
- NCI food and supplement interactions PDQ — Selected drug-specific food/ingredient interactions.
- NCI follow-up medical care — Individual follow-up plan and between-visit contact.
- NCI clinical-trial overview — Research participation and consent, not established individual benefit.
- AAD basal cell carcinoma patient guide — Selected local behaviour, superficial care and safety; no supported efficacy claim.
- AAD/AADA combined 2024 audited financial statements — Society revenue routes only; not clinical evidence.
- AAD corporate-support programme — Corporate support route; not evidence of a treatment effect.
- AAD office/contact information — Institutional location only.
- Shaheer A. Khan January/February 2026 financial disclosure — Financial declaration only; uveal-melanoma treatment claims not used.
- Regeneron second-quarter 2026 financial report — Manufacturer revenue and commercial interests only.
- Regeneron company locations — Manufacturer headquarters only, not a production-chain audit.
- Cemiplimab US prescribing information, revised August 2026 — Selected indication and serious safety warnings; no efficacy or dose conclusion.
- NCI budget and appropriations, May 2026 — Institutional appropriation route only.
- NCI Gift Fund and contribution routes, August 2025 — Separate gift route and office identity; no clinical evidence.
- NCI PDQ editorial boards, November 2022 — Board independence, honoraria and conflict-disclosure scope.
- NHS national content policy, October 2022 — Website funding and editorial safeguards only.
Educational research reviewed 4 October 2026. Diagnosis and treatment require a qualified clinician; this article does not provide an individual prescription or replace urgent assessment.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.